Sampre Nutritions Limited, a leading confectionery manufacturer, has received board approval for the issuance of foreign currency convertible bonds (FCCBs) totaling USD 4 crore, equivalent to ₹355.06 crore. The company will issue 400 FCCBs, each valued at USD 1,00,000, under the subscription terms of the FCCB issue.
The funds raised through this initiative will be directed towards expanding the company's global footprint, with emerging markets identified in Egypt and Liberia (Monrovia). The expansion aims to strengthen Sampre Nutritions’ presence in high-growth regions, diversify revenue streams, and capture opportunities in the international FMCG sector.
The company has appointed ARIES CAPITAL LIMITED as the Lead Arranger for listing and underwriting the FCCB issue. The FCCBs will be available for subscription on the AFRINEX EXCHANGE MAURITIUS from October 10, 2025 to October 15, 2025.
In its board meeting held on September 19, 2025, Sampre Nutritions approved a bonus issue and stock split. The board decided to split each equity share of face value ₹10 into two equity shares of ₹5 each.
Alongside this, a bonus issue in the ratio of 1:1 will be implemented, issuing one bonus equity share of ₹5 for every fully paid equity share of ₹5. The company will require ₹21.55 crore from its securities premium account to fund the bonus issue.
As per the audited financial statements for the year ended 31 March 2025, the company holds free reserves of ₹59.86 crore in the securities premium account. The bonus shares are expected to be credited on or before 19 December 2025.
Sampre Nutritions recently converted 550,000 warrants into equity shares. Of these, 500,000 were allotted to Mr. Brahma Gurbani, a promoter group member, and 50,000 to Mr. Vishal Ratan Gurbani. The conversion was completed for cash, upon realisation of 75% of the exercise price, amounting to ₹45.375 per warrant from the full price of ₹60.50 per warrant. This conversion follows a special resolution passed by shareholders on 8 December 2023 and the in-principle approval issued by BSE Limited on 29 October 2024. The original warrants were allotted on 13 November 2024.
Sampre Nutritions entered into a manufacturing agreement with Tolaram Wellness Ltd., Nigeria, dated 16 August 2025. Under this agreement, Sampre Nutritions will manufacture and supply nutraceutical and food products according to agreed specifications and quality standards. The contract is expected to generate approximately ₹10 crore annually, totaling around ₹30 crore over three years. Payment terms include 50% advance and the balance upon dispatch, with transportation costs borne by Tolaram Wellness.
Additionally, the company signed a three-year manufacturing agreement with Rama Exports on 19 August 2025 to produce nutraceutical and food products. This contract is projected to generate ₹15 crore in revenue over its tenure, reinforcing Sampre Nutritions’ operational depth and long-term partnerships in the nutraceutical and food sectors.
For Q1FY26 ending 30 June 2025, Sampre Nutritions reported revenue from operations of ₹10.87 crore, representing a 141% Y-o-Y growth from ₹4.51 crore in Q1FY25. Net profit for the quarter was ₹70.76 lakh, marking a 615% Y-o-Y increase compared to ₹9.89 lakh in Q1FY25.
The company has proposed a capital-raising initiative through preferential issues, qualified institutional placement (QIP), and public or private offerings. A board meeting will be arranged to seek shareholder approval for this fundraising initiative, aimed at strengthening the company’s financial structure and supporting ongoing expansion and diversification plans.
Sampre Nutritions Ltd has also been recognized with the Certificate of Recognition under the India 5000 Best MSME Awards 2024 for excellence in quality, customer satisfaction, and societal impact.
On Monday, Sampre Nutrition share price locked in the 2% upper circuit at ₹126.15 per share. The stock price has maintained a streak of 78 upper circuits, logging returns of over 400%.
For android only